Donanemab is the first amyloid plaque-targeting therapy approved in Singapore
Singapore, July 9, 2025 – DKSH Singapore is pleased to announce the approval of donanemab1 on March 11, 2025, in Singapore. Donanemab is the first amyloid plaque-targeting for Alzheimer’s disease approved in Singapore1. This landmark approval represents a significant advancement in the treatment landscape, marking a pivotal step forward in improving long-term outcomes to patients and caregivers.
Donanemab is indicated to slow disease progression in adult patients with Alzheimer’s disease (AD). Treatment with donanemab should be initiated in patients with evidence of amyloid beta pathology and either mild cognitive impairment or mild dementia1. By actively reducing these plaques, donanemab has been shown to slow the disease progression and preserve cognitive and functional abilities in patients2.
Key clinical data from the TRAILBLAZER-ALZ 2 study highlighted the efficacy of donanemab in slowing cognitive and functional decline in patients with early-stage Alzheimer’s disease2. The study showed that patients receiving donanemab experienced a 35% reduction in disease progression rate compared to placebo2. Additionally, 47% of patients on donanemab showed no meaningful decline in daily living activities at 12 months, compared to 29% on placebo3.
With its approval, donanemab, manufactured by Eli Lilly and Company, offers a much-needed option for early Alzheimer’s patients, reinforcing Singapore’s commitment to advancing neurological care4 and innovation.
As a strategic partner of Lilly, DKSH Singapore is proud to bring this breakthrough treatment to patients. Our dedication to improving patient access to innovative healthcare solutions is in line with our purpose to enriching lives, bringing healthcare for all. As part of this partnership, DKSH is committed to ensuring that patients and healthcare professionals have access to the latest developments in Alzheimer’s treatment.
About DKSH
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, over-the-counter products, and medical devices. With around 7,940 specialists, the Business Unit generated net sales of CHF 5.7 billion in 2024. www.dksh.com/hec